Bausch Health Companies (BHC) PT Lowered to $14 at Stifel
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
Go back to Bausch Health Companies (BHC) PT Lowered to $14 at Stifel
November 3, 2022 7:01 AM EDT
Revenues of $2.046 billion, down 3% reported, up 2% organic basisThird quarter sales improved sequentially, notably Salix, International, and SoltaSuccessful debt exchange offer reduces debt by $2.5 billionCompany updates full year guidance
LAVAL, QC / ACCESSWIRE / November 3, 2022 / Bausch Health Companies Inc. (NYSE: BHC)(TSX: BHC) ("Bausch Health" or the "Company" or "we" or "our") today announced its third-quarter 2022 financial results.
"We are encouraged with the top line... More
November 1, 2022 8:01 AM EDT
Nine Poster Presentations Include New Analyses of SILIQ and JUBLIA
LAVAL, QC / ACCESSWIRE / November 1, 2022 / - Bausch Health Companies Inc. (NYSE: BHC)(TSX: BHC) ("Bausch Health") and its dermatology business, Ortho Dermatologics, today announced the presentation of nine posters during the Innovations in Dermatology Conference, which takes place Nov. 3-5, 2022, in Las Vegas, Nev. The presentations will feature new data around JUBLIA (efinaconazole) Topical Solution, 10%, and SILIQ (brodalumab) Injection, 210 mg/1.5 mL. There will also be six encore presentations, including analyses of DUOBRII (halobetasol propionate and... More
